Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation

Simona Soverini, Michele Cavo, Claudia Cellini, Carolina Terragna, Elena Zamagni, Deborah Ruggeri, Nicoletta Testoni, Patrizia Tosi, Antonio De Vivo, Marilina Amabile, Tiziana Grafone, Emanuela Ottaviani, Barbara Giannini, Delia Cangini, Francesca Bonifazi, Antonino Neri, Sonia Fabris, Sante Tura, Michele Baccarani, Giovanni Martinelli

Research output: Contribution to journalArticlepeer-review

Abstract

We used a sensitive real-time reverse transcription-polymerase chain reaction assay to quantify cyclin D1 mRNA levels in bone marrow samples collected at diagnosis from 74 newly diagnosed multiple myeloma (MM) patients who were randomized to undergo either single or double autologous peripheral blood stem cell transplantation as part of first-line therapy for their malignancy. In 46 cases, fluorescence in situ hybridization (FISH) analysis and/or conventional cytogenetics were performed to detect chromosome 11 abnormalities. Patients with the t(11;14) or trisomy 11 significantly overexpressed cyclin D1 (P <.0001) in comparison with patients without 11q abnormalities, who had cyclin D1 mRNA levels similar to healthy donors. Overall, 32 (43%) of 74 patients showed cyclin D1 overexpression. No difference was found between cyclin D1-positive (group A) and cyclin D1-negative (group B) patients with respect to presenting clinical and laboratory characteristics, including chromosome 13 abnormalities, as well as to response to therapy and overall survival, both of which were calculated on an intent-to-treat basis. Patients who overexpressed cyclin D1 had significantly longer duration of remission in comparison with patients who did not (41 vs 26 months, respectively; P = .02). As a result, median event-free survival (EFS) was longer in group A than in group B (33 vs 24 months, respectively; P = 055). We concluded that cyclin D1 overexpression is closely associated with 11q abnormalities and identifies a subset of MM patients who are more likely to have prolonged duration of remission and EFS following autologous transplantation.

Original languageEnglish
Pages (from-to)1588-1594
Number of pages7
JournalBlood
Volume102
Issue number5
DOIs
Publication statusPublished - Sep 1 2003

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation'. Together they form a unique fingerprint.

Cite this